Trial Profile
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms POLO
- Sponsors AstraZeneca
- 22 Feb 2023 Results of post-hoc analysis assessing patient-centered outcomes were published in the Cancer.
- 09 Feb 2023 Status changed from active, no longer recruiting to completed.
- 09 Feb 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record (17 Jan 2023)